178 related articles for article (PubMed ID: 27184624)
1. Administrative Claims Data for Economic Analyses in Hematopoietic Cell Transplantation: Challenges and Opportunities.
Preussler JM; Mau LW; Majhail NS; Meyer CL; Denzen EM; Edsall KC; Farnia SH; Silver A; Saber W; Burns LJ; Vanness DJ
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1738-1746. PubMed ID: 27184624
[TBL] [Abstract][Full Text] [Related]
2. Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation.
Preussler JM; Meyer CL; Mau LW; Majhail NS; Denzen EM; Edsall KC; Farnia SH; Saber W; Burns LJ; Vanness DJ
Biol Blood Marrow Transplant; 2017 Jun; 23(6):1021-1028. PubMed ID: 28263920
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia.
Hagiwara M; Sharma A; Chung KC; Delea TE
J Med Econ; 2018 Nov; 21(11):1119-1130. PubMed ID: 30122084
[TBL] [Abstract][Full Text] [Related]
4. Increased Health Care Utilization and Costs during Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndromes in Adolescents and Young Adults Compared with Children: A Multicenter Study.
Rangarajan HG; Smith LC; Stanek JR; Hall M; Abu-Arja R; Auletta JJ; O'Brien SH
Biol Blood Marrow Transplant; 2019 May; 25(5):1031-1038. PubMed ID: 30625391
[TBL] [Abstract][Full Text] [Related]
5. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
[TBL] [Abstract][Full Text] [Related]
6. Enhancing Administrative Claims Data: Feasibility, Validation and Application of Linking Medicare Claims Data and National Marrow Donor Program Search Data.
Preussler JM; Meyer CL; Sees Coles JA; Yoo D; Mau LW; Garrett ND; Auletta JJ
JCO Clin Cancer Inform; 2022 Oct; 6():e2200069. PubMed ID: 36228178
[TBL] [Abstract][Full Text] [Related]
7. Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation.
Yu J; Lal L; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
Support Care Cancer; 2020 Nov; 28(11):5491-5499. PubMed ID: 32172407
[TBL] [Abstract][Full Text] [Related]
8. Medical costs of treatment and survival of patients with acute myeloid leukemia in Belgium.
Van de Velde AL; Beutels P; Smits EL; Van Tendeloo VF; Nijs G; Anguille S; Verlinden A; Gadisseur AP; Schroyens WA; Dom S; Cornille I; Goossens H; Berneman ZN
Leuk Res; 2016 Jul; 46():26-9. PubMed ID: 27111858
[TBL] [Abstract][Full Text] [Related]
9. The epidemiology, treatment patterns, healthcare utilizations and costs of Acute Myeloid Leukaemia (AML) in Taiwan.
Huang HH; Chen CM; Wang CY; Hsu WW; Chen HM; Ko BS; Hsiao FY
PLoS One; 2022; 17(1):e0261871. PubMed ID: 35061709
[TBL] [Abstract][Full Text] [Related]
10. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
Meyers J; Yu Y; Kaye JA; Davis KL
Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
[TBL] [Abstract][Full Text] [Related]
11. Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies.
Bonafede M; Richhariya A; Cai Q; Josephson NC; McMorrow D; Garfin PM; Perales MA
J Med Econ; 2017 Dec; 20(12):1244-1251. PubMed ID: 28782449
[TBL] [Abstract][Full Text] [Related]
12. Healthcare expenses for treatment of acute myeloid leukemia.
Bewersdorf JP; Shallis RM; Wang R; Huntington SF; Perreault S; Ma X; Zeidan AM
Expert Rev Hematol; 2019 Aug; 12(8):641-650. PubMed ID: 31159602
[No Abstract] [Full Text] [Related]
13. Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review.
Ashfaq K; Yahaya I; Hyde C; Andronis L; Barton P; Bayliss S; Chen YF
Health Technol Assess; 2010 Dec; 14(54):iii-iv, ix-xi, 1-141. PubMed ID: 21138675
[TBL] [Abstract][Full Text] [Related]
14. Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis.
Bonafede M; Anaissie E; Evans K; Itzler R
BMC Health Serv Res; 2021 Oct; 21(1):1125. PubMed ID: 34666775
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation.
Cheng WY; Avery RK; Thompson-Leduc P; Cheung HC; Bo T; Duh MS; Hirji I
J Med Econ; 2022; 25(1):367-380. PubMed ID: 35240904
[TBL] [Abstract][Full Text] [Related]
16. Sociodemographic disparities in chemotherapy and hematopoietic cell transplantation utilization among adult acute lymphoblastic and acute myeloid leukemia patients.
Jabo B; Morgan JW; Martinez ME; Ghamsary M; Wieduwilt MJ
PLoS One; 2017; 12(4):e0174760. PubMed ID: 28384176
[TBL] [Abstract][Full Text] [Related]
17. Clinical trajectories, healthcare resource use, and costs of long-term hematopoietic stem cell transplantation survivors: a latent class analysis.
Zhou J; Nutescu EA; Han J; Calip GS
J Cancer Surviv; 2020 Jun; 14(3):294-304. PubMed ID: 31897877
[TBL] [Abstract][Full Text] [Related]
18. Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database.
Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson S; Horvath Walsh LE; Wade RL
Adv Ther; 2019 Aug; 36(8):1922-1935. PubMed ID: 31222713
[TBL] [Abstract][Full Text] [Related]
19. Retrospective database analysis of healthcare resource utilization and costs in patients who develop post-transplant lymphoproliferative disease within the first year following allogeneic hematopoietic stem cell transplants.
Watson C; Xu H; Princic N; Sruti I; Barlev A
J Med Econ; 2020 Oct; 23(10):1159-1167. PubMed ID: 32643493
[TBL] [Abstract][Full Text] [Related]
20. The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands.
Leunis A; Blommestein HM; Huijgens PC; Blijlevens NM; Jongen-Lavrencic M; Uyl-de Groot CA
Leuk Res; 2013 Mar; 37(3):245-50. PubMed ID: 23069745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
